Symbols / ENLV $0.95 -1.07% Enlivex Ltd.
ENLV Chart
About
Enlivex Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra (ENX-CL-02-002), which is in phase II clinical trial for the treatment of organ dysfunction and failure caused by sepsis; and Allocetra (ENX-CL-05-001), which is in phase I/II clinical trial to treat moderate knee osteoarthritis. The company also develops 0189-22-KMC, which is in phase I/II clinical trial to treat end-stage knee osteoarthritis; 0006-24-KMC, which is in phase I/II clinical trial for the treatment of Basal thumb osteoarthritis; and ENX-CL-06-001 to treat Psoriatic arthritis and is in phase I/II clinical trial. Enlivex Ltd. was formerly known as Enlivex Therapeutics Ltd. and changed its name to Enlivex Ltd. in February 2026. The company was founded in 2005 and is headquartered in Ness Ziona, Israel.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 227.83M |
| Enterprise Value | 220.87M | Income | 1.24B | Sales | — |
| Book/sh | 8.15 | Cash/sh | 0.02 | Dividend Yield | — |
| Payout | 0.00% | Employees | 34 | IPO | — |
| P/E | 0.04 | Forward P/E | -1.22 | PEG | — |
| P/S | — | P/B | 0.12 | P/C | — |
| EV/EBITDA | -15.06 | EV/Sales | — | Quick Ratio | 0.69 |
| Current Ratio | 193.24 | Debt/Eq | 0.03 | LT Debt/Eq | — |
| EPS (ttm) | 25.48 | EPS next Y | -0.78 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-03-25 08:00 | ROA | -0.80% |
| ROE | 126.17% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 239.32M |
| Shs Float | 54.94M | Short Float | 0.22% | Short Ratio | 2.49 |
| Short Interest | — | 52W High | 2.10 | 52W Low | 0.66 |
| Beta | 1.68 | Avg Volume | 539.96K | Volume | 306.46K |
| Target Price | $13.00 | Recom | Buy | Prev Close | $0.96 |
| Price | $0.95 | Change | -1.07% |
Valuation Models
Price estimates from analyst targets and simple models.
Ratings
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-01-12 | main | HC Wainwright & Co. | Buy → Buy | $13 |
| 2025-11-24 | down | D. Boral Capital | Buy → Hold | — |
| 2025-10-29 | main | D. Boral Capital | Buy → Buy | $13 |
| 2025-09-26 | main | D. Boral Capital | Buy → Buy | $13 |
| 2025-09-12 | main | D. Boral Capital | Buy → Buy | $13 |
| 2025-09-02 | reit | HC Wainwright & Co. | Buy → Buy | $7 |
| 2025-08-22 | main | D. Boral Capital | Buy → Buy | $13 |
| 2025-08-18 | main | D. Boral Capital | Buy → Buy | $13 |
| 2025-07-29 | main | D. Boral Capital | Buy → Buy | $13 |
| 2025-07-22 | main | D. Boral Capital | Buy → Buy | $13 |
| 2025-04-21 | main | D. Boral Capital | Buy → Buy | $13 |
| 2025-04-03 | main | D. Boral Capital | Buy → Buy | $13 |
| 2025-03-24 | main | HC Wainwright & Co. | Buy → Buy | $7 |
| 2025-03-03 | main | D. Boral Capital | Buy → Buy | $13 |
| 2025-02-07 | main | D. Boral Capital | Buy → Buy | $13 |
| 2024-12-11 | main | D. Boral Capital | Buy → Buy | $13 |
| 2024-12-03 | main | D. Boral Capital | Buy → Buy | $13 |
| 2024-11-14 | main | D. Boral Capital | Buy → Buy | $13 |
| 2024-09-27 | reit | HC Wainwright & Co. | Buy → Buy | $6 |
| 2024-09-26 | main | EF Hutton | Buy → Buy | $13 |
- ENLV Apr 2026 0.500 put (ENLV260417P00000500) Stock Price, News, Quote & History - Yahoo! Finance Canada hu, 02 Apr 2026 14
- Biotech Enlivex shifts share trading to Nasdaq, leaves Tel Aviv in April - Stock Titan Fri, 23 Jan 2026 08
- ENLV: Analyst Raises Price Target Significantly | ENLV Stock New - GuruFocus Mon, 12 Jan 2026 08
- Enlivex Posts $1.23 Billion Profit for 2025 on Treasury Asset Gains - The Globe and Mail hu, 26 Mar 2026 13
- Treasury gains push Enlivex to $1.23B profit, $2.31B in assets - Stock Titan Wed, 25 Mar 2026 07
- ENLV Apr 2026 7.500 call (ENLV260417C00007500) Stock Price, News, Quote & History - Yahoo! Finance Canada Wed, 01 Apr 2026 03
- Enlivex Secures $21 Million Convertible Debt, Expands RAIN Token Holdings and Launches $20 Million Buyback - The Globe and Mail Wed, 25 Mar 2026 13
- Backed by $21M debt, Enlivex buys 3B more RAIN tokens at discount - Stock Titan ue, 24 Mar 2026 07
- ENLV Aug 2026 2.000 call (ENLV260821C00002000) Interactive Stock Chart - Yahoo! Finance Canada Mon, 30 Mar 2026 21
- One prompt can now create a live prediction market as Rain adds $5M - Stock Titan hu, 26 Mar 2026 07
- EXCLUSIVE: Enlivex Raises Over $200 Million To Launch First Public Company Prediction Markets Play - Yahoo Finance Mon, 24 Nov 2025 08
- Enlivex (Nasdaq: ENLV) raises $212M to launch RAIN prediction markets treasury plan - Stock Titan Mon, 24 Nov 2025 08
- Enlivex (NASDAQ: ENLV) director reports options on 150,000 shares in Form 3 - Stock Titan Wed, 18 Mar 2026 07
- RAIN token jumps to Kraken, second-largest US crypto exchange - Stock Titan ue, 10 Feb 2026 08
- Enlivex (ENLV) director Hart Gili reports option and share holdings - Stock Titan Wed, 18 Mar 2026 07
Insider Transactions
No recent insider transactions.
Financials
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Expense |
|
15.00
+0.46%
|
14.93
-40.63%
|
25.15
-2.50%
|
25.80
|
| Research And Development |
|
9.20
-13.36%
|
10.62
-44.12%
|
19.01
+1.71%
|
18.69
|
| Selling General And Administration |
|
5.68
+18.24%
|
4.81
-8.12%
|
5.23
-21.92%
|
6.70
|
| General And Administrative Expense |
|
5.68
+18.24%
|
4.81
-8.12%
|
5.23
-21.92%
|
6.70
|
| Salaries And Wages |
|
3.57
+11.83%
|
3.20
-0.93%
|
3.23
-15.24%
|
3.81
|
| Other Gand A |
|
1.83
+45.12%
|
1.26
-12.43%
|
1.44
-28.04%
|
2.00
|
| Other Operating Expenses |
|
0.11
+5.71%
|
0.10
-88.41%
|
0.91
+125.37%
|
0.40
|
| Total Expenses |
|
15.00
+0.46%
|
14.93
-40.63%
|
25.15
-2.50%
|
25.80
|
| Operating Income |
|
-15.00
-0.46%
|
-14.93
+40.63%
|
-25.15
+2.50%
|
-25.80
|
| Total Operating Income As Reported |
|
-15.03
+5.41%
|
-15.89
+45.95%
|
-29.39
-13.95%
|
-25.80
|
| EBITDA |
|
-14.67
-1.96%
|
-14.39
+40.84%
|
-24.32
+2.81%
|
-25.02
|
| Normalized EBITDA |
|
-1,647.06
-12333.48%
|
-13.25
+29.72%
|
-18.85
+0.46%
|
-18.94
|
| Reconciled Depreciation |
|
0.33
-39.08%
|
0.55
-34.73%
|
0.83
+7.46%
|
0.78
|
| EBIT |
|
-15.00
-0.46%
|
-14.93
+40.63%
|
-25.15
+2.50%
|
-25.80
|
| Total Unusual Items |
|
1,632.39
+143418.26%
|
-1.14
+79.17%
|
-5.47
+10.12%
|
-6.08
|
| Total Unusual Items Excluding Goodwill |
|
1,632.39
+143418.26%
|
-1.14
+79.17%
|
-5.47
+10.12%
|
-6.08
|
| Special Income Charges |
|
-0.03
+96.97%
|
-0.96
+77.45%
|
-4.24
|
0.00
|
| Net Income |
|
1,235.53
+8329.17%
|
-15.01
+48.35%
|
-29.07
+6.41%
|
-31.06
|
| Pretax Income |
|
1,618.17
+10877.77%
|
-15.01
+48.35%
|
-29.07
+6.41%
|
-31.06
|
| Net Non Operating Interest Income Expense |
|
0.78
-26.23%
|
1.06
-31.91%
|
1.55
+88.92%
|
0.82
|
| Net Interest Income |
|
0.78
-26.23%
|
1.06
-31.91%
|
1.55
+88.92%
|
0.82
|
| Interest Income Non Operating |
|
0.79
-25.91%
|
1.07
-31.69%
|
1.56
+87.43%
|
0.83
|
| Interest Income |
|
0.79
-25.91%
|
1.07
-31.69%
|
1.56
+87.43%
|
0.83
|
| Other Income Expense |
|
1,632.39
+143418.26%
|
-1.14
+79.17%
|
-5.47
+10.12%
|
-6.08
|
| Gain On Sale Of Security |
|
1,632.42
+897036.26%
|
-0.18
+85.13%
|
-1.22
+79.88%
|
-6.08
|
| Tax Provision |
|
382.65
|
0.00
|
0.00
|
—
|
| Tax Rate For Calcs |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Tax Effect Of Unusual Items |
|
386.06
|
0.00
|
0.00
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
1,235.53
+8329.17%
|
-15.01
+48.35%
|
-29.07
+6.41%
|
-31.06
|
| Net Income From Continuing Operation Net Minority Interest |
|
1,235.53
+8329.17%
|
-15.01
+48.35%
|
-29.07
+6.41%
|
-31.06
|
| Net Income From Continuing And Discontinued Operation |
|
1,235.53
+8329.17%
|
-15.01
+48.35%
|
-29.07
+6.41%
|
-31.06
|
| Net Income Continuous Operations |
|
1,235.53
+8329.17%
|
-15.01
+48.35%
|
-29.07
+6.41%
|
-31.06
|
| Normalized Income |
|
-10.81
+22.12%
|
-13.88
+41.21%
|
-23.60
+5.51%
|
-24.98
|
| Net Income Common Stockholders |
|
1,235.53
+8329.17%
|
-15.01
+48.35%
|
-29.07
+6.41%
|
-31.06
|
| Diluted EPS |
|
—
|
-0.73
+53.21%
|
-1.56
+7.69%
|
-1.69
|
| Basic EPS |
|
—
|
-0.73
+53.21%
|
-1.56
+7.69%
|
-1.69
|
| Basic Average Shares |
|
—
|
20.51
+10.44%
|
18.57
+0.98%
|
18.39
|
| Diluted Average Shares |
|
—
|
20.51
+10.44%
|
18.57
+0.98%
|
18.39
|
| Diluted NI Availto Com Stockholders |
|
1,235.53
+8329.17%
|
-15.01
+48.35%
|
-29.07
+6.41%
|
-31.06
|
| Gain On Sale Of PPE |
|
-0.03
+96.97%
|
-0.96
+77.45%
|
-4.24
|
0.00
|
| Insurance And Claims |
|
0.28
-19.94%
|
0.35
-38.10%
|
0.57
-36.65%
|
0.90
|
| Other Taxes |
|
0.00
+100.00%
|
-0.60
|
0.00
|
0.00
|
| Total Other Finance Cost |
|
0.01
+0.00%
|
0.01
-7.14%
|
0.01
+0.00%
|
0.01
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Assets |
|
2,327.00
+8304.66%
|
27.69
-24.83%
|
36.83
-45.55%
|
67.64
|
| Current Assets |
|
1,743.18
+6606.34%
|
25.99
-23.02%
|
33.76
-35.48%
|
52.33
|
| Cash Cash Equivalents And Short Term Investments |
|
5.75
-75.51%
|
23.50
-14.00%
|
27.32
-45.63%
|
50.24
|
| Cash And Cash Equivalents |
|
1.89
-42.62%
|
3.30
+306.03%
|
0.81
-98.37%
|
49.95
|
| Cash Equivalents |
|
0.31
-69.92%
|
1.04
|
0.00
-100.00%
|
47.82
|
| Cash Financial |
|
1.58
-30.00%
|
2.26
+177.61%
|
0.81
-61.71%
|
2.12
|
| Other Short Term Investments |
|
3.86
-80.88%
|
20.20
-23.81%
|
26.51
+8765.22%
|
0.30
|
| Receivables |
|
0.51
-63.96%
|
1.42
+517.90%
|
0.23
-64.61%
|
0.65
|
| Accounts Receivable |
|
—
|
—
|
—
|
—
|
| Other Receivables |
|
0.35
-74.16%
|
1.35
+1092.04%
|
0.11
-9.60%
|
0.12
|
| Taxes Receivable |
|
0.16
+138.24%
|
0.07
-41.38%
|
0.12
-77.78%
|
0.52
|
| Prepaid Assets |
|
3.85
+335.63%
|
0.88
-20.14%
|
1.11
-23.07%
|
1.44
|
| Restricted Cash |
|
—
|
—
|
—
|
0.11
|
| Assets Held For Sale Current |
|
0.00
-100.00%
|
0.20
-96.12%
|
5.11
|
0.00
|
| Hedging Assets Current |
|
1,708.79
|
0.00
|
—
|
—
|
| Other Current Assets |
|
24.27
|
—
|
—
|
—
|
| Total Non Current Assets |
|
583.82
+34363.99%
|
1.69
-44.77%
|
3.07
-79.97%
|
15.31
|
| Net PPE |
|
0.94
-18.65%
|
1.15
-55.31%
|
2.58
-82.68%
|
14.90
|
| Gross PPE |
|
4.78
-0.56%
|
4.80
-26.89%
|
6.57
-64.35%
|
18.43
|
| Accumulated Depreciation |
|
-3.84
-5.15%
|
-3.65
+8.52%
|
-3.99
-13.13%
|
-3.53
|
| Properties |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Machinery Furniture Equipment |
|
0.65
+10.75%
|
0.59
-0.85%
|
0.59
+12.57%
|
0.53
|
| Other Properties |
|
3.18
-2.75%
|
3.27
-28.10%
|
4.55
-51.08%
|
9.30
|
| Leases |
|
0.95
+0.00%
|
0.95
-33.82%
|
1.43
-83.37%
|
8.61
|
| Investments And Advances |
|
—
|
—
|
—
|
—
|
| Other Investments |
|
—
|
—
|
—
|
—
|
| Non Current Accounts Receivable |
|
—
|
0.21
|
—
|
—
|
| Non Current Prepaid Assets |
|
0.01
-55.56%
|
0.02
-90.37%
|
0.19
+65.49%
|
0.11
|
| Other Non Current Assets |
|
582.87
+183771.92%
|
0.32
+5.67%
|
0.30
+0.33%
|
0.30
|
| Total Liabilities Net Minority Interest |
|
392.05
+9466.86%
|
4.10
-39.26%
|
6.75
-37.53%
|
10.80
|
| Current Liabilities |
|
9.02
+137.46%
|
3.80
-37.32%
|
6.06
-8.26%
|
6.61
|
| Payables And Accrued Expenses |
|
6.04
+199.50%
|
2.02
-43.92%
|
3.59
-30.84%
|
5.20
|
| Payables |
|
3.81
+369.54%
|
0.81
-1.93%
|
0.83
-57.55%
|
1.95
|
| Accounts Payable |
|
3.81
+369.54%
|
0.81
-1.93%
|
0.83
-57.55%
|
1.95
|
| Current Accrued Expenses |
|
2.23
+84.97%
|
1.20
-56.47%
|
2.77
-14.81%
|
3.25
|
| Pensionand Other Post Retirement Benefit Plans Current |
|
2.73
+93.89%
|
1.41
+58.27%
|
0.89
+17.13%
|
0.76
|
| Current Debt And Capital Lease Obligation |
|
0.26
+9.79%
|
0.23
-32.08%
|
0.35
-47.01%
|
0.65
|
| Current Capital Lease Obligation |
|
0.26
+9.79%
|
0.23
-32.08%
|
0.35
-47.01%
|
0.65
|
| Other Current Liabilities |
|
—
|
0.14
-88.48%
|
1.23
|
—
|
| Total Non Current Liabilities Net Minority Interest |
|
383.03
+128003.34%
|
0.30
-56.41%
|
0.69
-83.64%
|
4.19
|
| Long Term Debt And Capital Lease Obligation |
|
0.38
+28.09%
|
0.30
-56.41%
|
0.69
-83.64%
|
4.19
|
| Long Term Capital Lease Obligation |
|
0.38
+28.09%
|
0.30
-56.41%
|
0.69
-83.64%
|
4.19
|
| Non Current Deferred Liabilities |
|
382.65
|
0.00
|
—
|
—
|
| Non Current Deferred Taxes Liabilities |
|
382.65
|
0.00
|
—
|
—
|
| Other Non Current Liabilities |
|
—
|
—
|
—
|
—
|
| Stockholders Equity |
|
1,934.95
+8102.76%
|
23.59
-21.59%
|
30.08
-47.07%
|
56.84
|
| Common Stock Equity |
|
1,934.95
+8102.76%
|
23.59
-21.59%
|
30.08
-47.07%
|
56.84
|
| Capital Stock |
|
28.73
+970.02%
|
2.69
+25.64%
|
2.14
+0.94%
|
2.12
|
| Common Stock |
|
28.73
+970.02%
|
2.69
+25.64%
|
2.14
+0.94%
|
2.12
|
| Share Issued |
|
237.38
+903.69%
|
23.65
+27.17%
|
18.60
+0.96%
|
18.42
|
| Ordinary Shares Number |
|
237.38
+903.69%
|
23.65
+27.17%
|
18.60
+0.96%
|
18.42
|
| Additional Paid In Capital |
|
796.70
+442.30%
|
146.91
+5.74%
|
138.94
+1.68%
|
136.65
|
| Retained Earnings |
|
1,108.42
+972.04%
|
-127.11
-13.39%
|
-112.09
-35.01%
|
-83.03
|
| Gains Losses Not Affecting Retained Earnings |
|
1.10
+0.00%
|
1.10
+0.00%
|
1.10
+0.00%
|
1.10
|
| Other Equity Adjustments |
|
1.10
+0.00%
|
1.10
+0.00%
|
1.10
|
—
|
| Total Equity Gross Minority Interest |
|
1,934.95
+8102.76%
|
23.59
-21.59%
|
30.08
-47.07%
|
56.84
|
| Total Capitalization |
|
1,934.95
+8102.76%
|
23.59
-21.59%
|
30.08
-47.07%
|
56.84
|
| Working Capital |
|
1,734.16
+7713.63%
|
22.19
-19.89%
|
27.70
-39.41%
|
45.72
|
| Invested Capital |
|
1,934.95
+8102.76%
|
23.59
-21.59%
|
30.08
-47.07%
|
56.84
|
| Total Debt |
|
0.64
+20.04%
|
0.53
-48.26%
|
1.03
-78.71%
|
4.85
|
| Capital Lease Obligations |
|
0.64
+20.04%
|
0.53
-48.26%
|
1.03
-78.71%
|
4.85
|
| Net Tangible Assets |
|
1,934.95
+8102.76%
|
23.59
-21.59%
|
30.08
-47.07%
|
56.84
|
| Tangible Book Value |
|
1,934.95
+8102.76%
|
23.59
-21.59%
|
30.08
-47.07%
|
56.84
|
| Dueto Related Parties Current |
|
—
|
—
|
—
|
—
|
| Foreign Currency Translation Adjustments |
|
—
|
—
|
1.10
+0.00%
|
1.10
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-10.42
+19.93%
|
-13.01
+44.70%
|
-23.52
+1.80%
|
-23.95
|
| Cash Flow From Continuing Operating Activities |
|
-10.42
+19.93%
|
-13.01
+44.70%
|
-23.52
+1.80%
|
-23.95
|
| Net Income From Continuing Operations |
|
1,235.53
+8329.17%
|
-15.01
+48.35%
|
-29.07
+6.41%
|
-31.06
|
| Depreciation Amortization Depletion |
|
0.33
-39.08%
|
0.55
-34.73%
|
0.83
+7.46%
|
0.78
|
| Depreciation |
|
0.33
-39.08%
|
0.55
-34.73%
|
0.83
+7.46%
|
0.78
|
| Depreciation And Amortization |
|
0.33
-39.08%
|
0.55
-34.73%
|
0.83
+7.46%
|
0.78
|
| Other Non Cash Items |
|
0.26
-11.45%
|
0.30
-57.33%
|
0.70
-16.25%
|
0.83
|
| Pension And Employee Benefit Expense |
|
—
|
—
|
—
|
—
|
| Stock Based Compensation |
|
1.78
-13.66%
|
2.06
+5.84%
|
1.95
-28.06%
|
2.71
|
| Deferred Tax |
|
382.65
|
0.00
|
0.00
|
—
|
| Deferred Income Tax |
|
382.65
|
0.00
|
0.00
|
—
|
| Operating Gains Losses |
|
-0.51
-260.25%
|
0.32
-91.83%
|
3.88
+95.71%
|
1.98
|
| Gain Loss On Investment Securities |
|
-0.54
+3.94%
|
-0.56
-62.68%
|
-0.34
-117.30%
|
1.98
|
| Unrealized Gain Loss On Investment Securities |
|
-1,631.28
|
0.00
|
0.00
|
—
|
| Gain Loss On Sale Of PPE |
|
-0.00
+98.78%
|
-0.08
-310.00%
|
-0.02
|
—
|
| Change In Working Capital |
|
0.81
+166.91%
|
-1.22
+33.00%
|
-1.82
-326.12%
|
0.80
|
| Change In Prepaid Assets |
|
-3.05
-804.62%
|
0.43
-28.78%
|
0.61
+118.71%
|
0.28
|
| Change In Payables And Accrued Expense |
|
4.07
+484.15%
|
-1.06
+27.94%
|
-1.47
-179.43%
|
1.85
|
| Change In Accrued Expense |
|
1.07
+202.97%
|
-1.04
-198.29%
|
-0.35
-151.17%
|
0.68
|
| Change In Payable |
|
3.00
+18831.25%
|
-0.02
+98.57%
|
-1.12
-195.98%
|
1.17
|
| Change In Account Payable |
|
3.00
+18831.25%
|
-0.02
+98.57%
|
-1.12
-195.98%
|
1.17
|
| Change In Other Current Liabilities |
|
-0.21
+65.14%
|
-0.59
+38.12%
|
-0.95
+27.98%
|
-1.33
|
| Investing Cash Flow |
|
-1.32
-114.60%
|
9.06
+134.89%
|
-25.97
-141.53%
|
62.52
|
| Cash Flow From Continuing Investing Activities |
|
-1.32
-114.60%
|
9.06
+134.89%
|
-25.97
-141.53%
|
62.52
|
| Net PPE Purchase And Sale |
|
-0.07
-182.72%
|
0.08
+178.64%
|
-0.10
+98.73%
|
-8.12
|
| Purchase Of PPE |
|
-0.07
+33.98%
|
-0.10
+56.36%
|
-0.24
+97.09%
|
-8.12
|
| Sale Of PPE |
|
0.00
-99.46%
|
0.18
+38.35%
|
0.13
|
0.00
|
| Capital Expenditure |
|
-0.07
+33.98%
|
-0.10
+56.36%
|
-0.24
+97.09%
|
-8.12
|
| Net Investment Purchase And Sale |
|
-1.26
-113.99%
|
8.98
+134.71%
|
-25.86
-136.61%
|
70.65
|
| Purchase Of Investment |
|
-44.00
-35.92%
|
-32.37
-23.71%
|
-26.17
-1272.10%
|
-1.91
|
| Sale Of Investment |
|
42.74
+3.37%
|
41.35
+13636.88%
|
0.30
-99.59%
|
72.55
|
| Financing Cash Flow |
|
10.38
+60.85%
|
6.45
+1692.78%
|
0.36
+140.00%
|
0.15
|
| Cash Flow From Continuing Financing Activities |
|
10.38
+60.85%
|
6.45
+1692.78%
|
0.36
+140.00%
|
0.15
|
| Net Common Stock Issuance |
|
10.38
+60.90%
|
6.45
+1692.22%
|
0.36
|
0.00
|
| Proceeds From Stock Option Exercised |
|
0.00
-100.00%
|
0.00
|
0.00
-100.00%
|
0.15
|
| Changes In Cash |
|
-1.36
-154.21%
|
2.50
+105.10%
|
-49.13
-226.88%
|
38.72
|
| Effect Of Exchange Rate Changes |
|
—
|
—
|
0.00
|
0.00
|
| Beginning Cash Position |
|
3.73
+204.32%
|
1.23
-97.57%
|
50.36
+332.77%
|
11.64
|
| End Cash Position |
|
2.37
-36.40%
|
3.73
+204.32%
|
1.23
-97.57%
|
50.36
|
| Free Cash Flow |
|
-10.48
+20.04%
|
-13.11
+44.82%
|
-23.76
+25.93%
|
-32.08
|
| Income Tax Paid Supplemental Data |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Common Stock Issuance |
|
10.38
+60.90%
|
6.45
+1692.22%
|
0.36
|
0.00
|
| Issuance Of Capital Stock |
|
10.38
+60.90%
|
6.45
+1692.22%
|
0.36
|
0.00
|
SEC Filings
No SEC filings found for this symbol (may be non-US or ticker not in SEC index).
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|